Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.
The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera. Incyte has expanded its JAK franchise with the topical formulation Opzelura® (ruxolitinib cream), which is approved for atopic dermatitis and vitiligo. Beyond JAK inhibition, the company maintains a deep pipeline that includes programs targeting IDO1, PI3Kδ and PD-1/PD-L1, among other mechanisms, with candidates in various stages of clinical development.
Incyte conducts clinical trials and commercial operations across North America, Europe and the Asia-Pacific region. The company has established strategic collaborations and licensing agreements with several global partners to extend its reach and leverage complementary expertise in regulatory affairs, manufacturing and marketing.
Leadership at Incyte is headed by President and Chief Executive Officer Hervé Hoppenot, who brings extensive experience in global biopharmaceutical management. Under his stewardship, the company continues to prioritize innovation, rigorous clinical investigation and patient access to new therapies.